Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01376089 · ClinicalTrials.gov registry record · Phase 4
Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis
A Phase 4 study of Patient Comfort and Safety, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 4
- Development phase
- 304
- Enrollment target
- 1
- Study location
NCT01376089: Completed Phase 4 study of Patient Comfort and Safety, sponsored by GE Healthcare.
NCT01376089 is a Phase 4 study of Patient Comfort and Safety that has completed, run by GE Healthcare. The registered enrollment target is 304 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01376089, a Phase 4 study of Patient Comfort and Safety, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 304 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate and compare overall patient comfort profile between the Iso-osmolar contrast media (IOCM), iodixanol 320 mg I/mL, and a Low-osmolar contrast media (LOCM), iopamidol 370 mg I/mL in patients undergoing Contrast-Enhanced Computed Tomographic (CECT) imaging of the abdomen/pelvis.
Primary Outcome
Number of subjects experiencing any moderate (score of 4 - 7) to severe (score 8 - 10) discomfort for cold or heat or pain between Iodixanol and Iopamidol.
Conditions Studied
Interventions
- DRUG Iopamidol
- DRUG Iodixanol
Study Locations (1)
New Jersey
- GE Healthcare - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-02 |
| Phase | Phase 4 |
What the finished NCT01376089 record still lists
NCT01376089 is an interventional study that assigns participants to a tested intervention. The registered 304 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (41% lower).
The record links to 1 condition, with Patient Comfort and Safety appearing as the primary indexed condition, and to 2 interventions - of which Iopamidol is the first listed.
NCT01376089 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT01376089 about?
NCT01376089 is a clinical study titled "Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis". The purpose of this study is to evaluate and compare overall patient comfort profile between the Iso-osmolar contrast media (IOCM), iodixanol 320 mg I/mL, and a Low-osmolar contrast media (LOCM), iopamidol 370 mg I/mL in patients undergoing Contrast-Enhanced Computed Tomographic (CECT) imaging of th...
What is the current status of trial NCT01376089?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 304 participants. The study started on 2011-05. Estimated completion is 2012-02.
What conditions does trial NCT01376089 study?
This clinical trial studies the following conditions: Patient Comfort and Safety.
What interventions are being tested in trial NCT01376089?
The interventions under investigation include: Iopamidol (DRUG), Iodixanol (DRUG).
Who is sponsoring clinical trial NCT01376089?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01376089 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01376089's enrollment target sits among peer trials
304 264th of 2000 higher than 1,736 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04750616 · 304 participants · Phase 2
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
- NCT04994717 · 304 participants · Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- NCT06036147 · 304 participants · NA
Concussion Health Improvement Program
- NCT06096844 · 304 participants · Phase 3
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia